Sign Up
OverviewAPI
Eli Lilly reports strong profits driven by the success of diabetes and weight loss drugs, with Mounjaro generating $2.2 billion and Zepbound contributing $175.8 million. The company revised its sales forecasts for 2024, estimating annual sales in the range of $40.4 billion to $41.6 billion.

Ask a question